Search Results - "NEGORO, S"

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan by Ohe, Y., Ohashi, Y., Kubota, K., Tamura, T., Nakagawa, K., Negoro, S., Nishiwaki, Y., Saijo, N., Ariyoshi, Y., Fukuoka, M.

“…Background: To compare the efficacy and toxicity of three platinum-based combination regimens against cisplatin plus irinotecan (IP) in patients with untreated…”
Get full text

Biodegradation of nylon oligomers by NEGORO, S

“…This mini-review is a compendium of the degradation of a man-made compound, 6-aminohexanoate-oligomer, in Flavobacterium strains. The results are summarized as…”
Get full text

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) by Tamura, K, Okamoto, I, Kashii, T, Negoro, S, Hirashima, T, Kudoh, S, Ichinose, Y, Ebi, N, Shibata, K, Nishimura, T, Katakami, N, Sawa, T, Shimizu, E, Fukuoka, J, Satoh, T, Fukuoka, M

“…The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of screening for epidermal growth factor receptor ( EGFR ) mutations…”
Get full text

A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy by Tanioka, M, Kitao, A, Matsumoto, K, Shibata, N, Yamaguchi, S, Fujiwara, K, Minami, H, Katakami, N, Morita, S, Negoro, S

“…Background: We evaluated the efficacy of aprepitant plus granisetron and an increased dose of dexamethasone in selected patients undergoing moderately…”
Get full text

Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104) by Takeda, K., Negoro, S., Tamura, T., Nishiwaki, Y., Kudoh, S., Yokota, S., Matsui, K., Semba, H., Nakagawa, K., Takada, Y., Ando, M., Shibata, T., Saijo, N.

“…This trial evaluated whether a combination of docetaxel and gemcitabine provides better survival than docetaxel alone in patients with previously treated…”
Get full text

Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study) by Hata, A., Katakami, N., Nishino, K., Mori, M., Yokoyama, T., Kurata, T., Tachihara, M., Takase, N., Daga, H., Kijima, T., Morita, S., Sakai, K., Nishio, K., Satouchi, M., Negoro, S.

Get full text

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors by Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Yamamoto, N., Takeda, K., Swaisland, H., Nakatani, I., Hirose, M., Dong, R.-P., Fukuoka, M.

“…Background: This phase I dose-escalating study investigated the tolerability and toxicity of the selective epidermal growth factor receptor tyrosine kinase…”
Get full text

STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart by OSHIMA, Yuichi, FUJIO, Yasushi, NAKANISHI, Tsuyoshi, ITOH, Norio, YAMAMOTO, Yasuhiro, NEGORO, Shinji, TANAKA, Keiichi, KISHIMOTO, Tadamitsu, KAWASE, Ichiro, AZUMA, Junichi

“…Activation of signal transducer and activator of transcription 3 (STAT3) was reported to be correlated with myocardial protection against ischemia/reperfusion…”
Get full text

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer by Tanioka, M., Sakai, K., Sudo, T., Sakuma, T., Kajimoto, K., Hirokaga, K., Takao, S., Negoro, S., Minami, H., Nakagawa, K., Nishio, K.

“…Several trials have confirmed that the pathological complete response (pCR) rates after neoadjuvant chemotherapy (NAC) are significantly lower in…”
Get full text

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer by NEGORO, S, MASUDA, N, TAKADA, Y, SUGIURA, T, KUDOH, S, KATAKAMI, N, ARIYOSHI, Y, OHASHI, Y, NIITANI, H, FUKUOKA, M

“…To determine a standard combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC), we conducted a phase III trial of irinotecan…”
Get full text

Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction by NEGORO, Shinji, KUNISADA, Keita, TONE, Eiroh, FUNAMOTO, Masanobu, OH, Hidemasa, KISHIMOTO, Tadamitsu, YAMAUCHI-TAKIHARA, Keiko

“…We reported that the activation of gp130 transduced hypertrophic and cytoprotective signals via Janus kinase/signal transducer and activator of transcription…”
Get full text

A phase I study of pemetrexed (LY23I5I4) supplemented with folate and vitamin B12 in japanese patients with solid tumours by NAKAGAWA, K, KUDOH, S, MATSUI, K, NEGORO, S, YAMAMOTO, N, LATZ, J. E, ADACHI, S, FUKUOKA, M

“…The purpose of this study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of pemetrexed with folate and vitamin B12 supplementation…”
Get full text

Phase I–II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer by Ohe, Y., Negoro, S., Matsui, K., Nakagawa, K., Sugiura, T., Takada, Y., Nishiwaki, Y., Yokota, S., Kawahara, M., Saijo, N., Fukuoka, M., Ariyoshi, Y.

“…Background: Amrubicin, a totally synthetic 9-amino-anthracycline, demonstrated excellent single-agent activity for extensive-stage small-cell lung cancer…”
Get full text

PO-0681: Improved prediction of severe radiation pneumonitis by combining V20, VS5, pulmonary fibrosis on CT, and age by Tsujino, K, Hashimoto, T, Shimada, T, Ota, Y, Muraoka, O, Kawaguchi, H, Satouchi, M, Negoro, S, Adachi, S, Soejima, T

Get full text

Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel by Sekine, I., Ichinose, Y., Nishiwaki, Y., Yamamoto, N., Tsuboi, M., Nakagawa, K., Shinkai, T., Negoro, S., Imamura, F., Eguchi, K., Takeda, K., Itoh, Y., Tamura, T., Saijo, N., Fukuoka, M.

“…This report describes quality of life (QoL) findings of a randomized study comparing gefitinib with docetaxel in patients with advanced/metastatic pretreated…”
Get full text

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib by SATOUCHI, M, NEGORO, S, TAKADA, Y, YATABE, Y, MITSUDOMI, T, FUNADA, Y, URATA, Y, SHIMADA, T, YOSHIMURA, S, KOTANI, Y, SAKUMA, T, WATANABE, H, ADACHI, S

“…This study aimed to identify predictive factors associated with prognostic benefits of gefitinib. A total of 221 Japanese patients who received gefitinib (250…”
Get full text

Randomised phase II study of docetaxel/cisplatin vs docetaxel/ irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803) by YAMAMOTO, N, FUKUOKA, M, NAKANO, T, KATAKAMI, N, SUGIURA, T, HOSO, T, ARIYOSHI, Y, NEGORO, S-I, NAKAGAWA, K, SAITO, H, MATSUI, K, KAWAHARA, M, SENBA, H, TAKADA, Y, KUDOH, S

“…Docetaxel plus cisplatin and docetaxel plus irinotecan are active and well-tolerated chemotherapy regimens for advanced non-small-cell lung cancer (NSCLC). A…”
Get full text

9109 POSTER A Phase II Study of Pemetrexed in Heavily Pretreated Non-squamous Non Small Cell Lung Cancer – HANSHIN Oncology Group 001 by Fujita, S, Katakami, N, Hattori, Y, Satouchi, M, Uchida, J, Imamura, F, Yokota, S, Kotani, Y, Nishimura, T, Negoro, S

Get full text

9008 ORAL Randomized Phase III Trial of Adjuvant Chemotherapy With Gemcitabine Compared With Oral Tegafur-uracil (UFT) in Resected, Stage IB-llla Non-small Cell Lung Cancer (WJTOG 0101) by Mitsudomi, T, Tada, H, Ichinose, Y, Yokoi, K, Katakami, N, Oda, M, Negoro, S, Chiba, Y, Nakagawa, K, Nakanishi, Y

Get full text

Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer by TSUDA, H, HASHIGUCHI, Y, NISHIMURA, S, MIYAMA, M, NAKATA, S, KAWAMURA, N, NEGORO, S

“…Combination chemotherapy with irinotecan (CPT-11) and platinum compounds is effective for treating cervical cancer. Nedaplatin (254-S) is a new cisplatin…”
Get full text